Kenneth L Kehl1,2, Shihao Yang3, Mark M Awad4, Nathan Palmer5, Isaac S Kohane5, Deborah Schrag6. 1. Division of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA. Kenneth_Kehl@dfci.harvard.edu. 2. Thoracic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA. Kenneth_Kehl@dfci.harvard.edu. 3. Department of Statistics, Harvard University, Boston, MA, USA. 4. Thoracic Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA. 5. Department of Bioinformatics, Harvard Medical School, Boston, MA, USA. 6. Division of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Abstract
INTRODUCTION: Patients with pre-existing autoimmune diseases have been excluded from clinical trials of immune checkpoint inhibitors (ICIs) for cancer. Real-world evidence is necessary to understand ICI safety in this population. METHODS: Patients treated with ICIs from 2011 to 2017 were identified using data from a large health insurer. Outcomes included time to (1) any hospitalization; (2) any hospitalization with an irAE diagnosis; and (3) outpatient corticosteroid treatment. The key exposure was pre-existing autoimmune disease, ascertained within 12 months before starting ICI treatment, and defined either by strict criteria (one inpatient or two outpatient claims at least 30 days apart) or relaxed criteria only (any claim, without meeting strict criteria). RESULTS: Of 4438 ICI-treated patients, pre-existing autoimmune disease was present among 179 (4%) by strict criteria, and another 283 (6%) by relaxed criteria only. In multivariable models, pre-existing autoimmune disease by strict criteria was not associated with all-cause hospitalization (HR 1.27, 95% CI 0.998-1.62), but it was associated with hospitalization with an irAE diagnosis (HR 1.81, 95% CI 1.21-2.71) and with corticosteroid treatment (HR 1.93, 95% CI 1.35-2.76). Similarly, pre-existing autoimmune disease by relaxed criteria only was not associated with all-cause hospitalization (HR 1.11, 95% CI 0.91-1.34), but was associated with hospitalization with an irAE diagnosis (HR 1.46, 95% CI 1.06-2.01) and corticosteroid treatment (HR 1.46, 95% CI 1.13-1.88). CONCLUSION: Pre-existing autoimmune disease was not associated with time to any hospitalization after initiating ICI therapy, but it was associated with a modest increase in hospitalizations with irAE diagnoses and with corticosteroid treatment.
INTRODUCTION:Patients with pre-existing autoimmune diseases have been excluded from clinical trials of immune checkpoint inhibitors (ICIs) for cancer. Real-world evidence is necessary to understand ICI safety in this population. METHODS:Patients treated with ICIs from 2011 to 2017 were identified using data from a large health insurer. Outcomes included time to (1) any hospitalization; (2) any hospitalization with an irAE diagnosis; and (3) outpatient corticosteroid treatment. The key exposure was pre-existing autoimmune disease, ascertained within 12 months before starting ICI treatment, and defined either by strict criteria (one inpatient or two outpatient claims at least 30 days apart) or relaxed criteria only (any claim, without meeting strict criteria). RESULTS: Of 4438 ICI-treated patients, pre-existing autoimmune disease was present among 179 (4%) by strict criteria, and another 283 (6%) by relaxed criteria only. In multivariable models, pre-existing autoimmune disease by strict criteria was not associated with all-cause hospitalization (HR 1.27, 95% CI 0.998-1.62), but it was associated with hospitalization with an irAE diagnosis (HR 1.81, 95% CI 1.21-2.71) and with corticosteroid treatment (HR 1.93, 95% CI 1.35-2.76). Similarly, pre-existing autoimmune disease by relaxed criteria only was not associated with all-cause hospitalization (HR 1.11, 95% CI 0.91-1.34), but was associated with hospitalization with an irAE diagnosis (HR 1.46, 95% CI 1.06-2.01) and corticosteroid treatment (HR 1.46, 95% CI 1.13-1.88). CONCLUSION: Pre-existing autoimmune disease was not associated with time to any hospitalization after initiating ICI therapy, but it was associated with a modest increase in hospitalizations with irAE diagnoses and with corticosteroid treatment.
Authors: Andrea Antonuzzo; Fabio Calabrò; Pietro Quaglino; Fausto Roila; Gian Domenico Sebastiani; Francesco Spina; Giuseppe Pasqualetti; Diego Cortinovis; Enrico Tagliaferri; Alessandro Peri; Elena Margherita Presotto; Maria Francesca Egidi; Luca Giacomelli; Ferruccio Farroni; Massimo Di Maio; Emmanuele De Luca; Marco Danova; Florian Scottè; Karin Jordan; Paolo Bossi Journal: Oncologist Date: 2020-03-17
Authors: Sebastian Krammer; Christian Krammer; Suzanna Salzer; Işin Sinem Bağci; Lars E French; Daniela Hartmann Journal: Front Med (Lausanne) Date: 2019-11-12
Authors: Rik J Verheijden; Anne M May; Christian U Blank; Astrid A M van der Veldt; Marye J Boers-Sonderen; Maureen J B Aarts; Franchette W P J van den Berkmortel; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; Jacobus J M van der Hoeven; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Albert J Ten Tije; Gerard Vreugdenhil; Michiel C T van Zeijl; Michel W J M Wouters; John B A G Haanen; Ellen Kapiteijn; Karijn P M Suijkerbuijk Journal: ESMO Open Date: 2020-11
Authors: Vickie R Shannon; Ronald Anderson; Ada Blidner; Jennifer Choi; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas B Johnson; Maria E Suarez-Almazor; Bernardo L Rapoport Journal: Support Care Cancer Date: 2020-09-03 Impact factor: 3.603